Валеология: Здоровье, Болезнь, Выздоровление. 2021; : 102-106
ПРИЧИНЫ ВОЗНИКНОВЕНИЯ НИЗКОРОСЛОСТИ У ДЕТЕЙ И ПОДРОСТКОВ
Аннотация
Гетерогенное состояние обуславливает задержку роста у детей. Для его понимания и анализа необходим многогранный подход, объясняющий течение данной группы заболеваний. Карликовым считается рост у мужчин ниже 135 см и у женщин менее 125 см. В большинстве случаев эндокринные, соматические, генетические и хромосомные заболевания сопровождаются задержкой роста, вследствие этого возникают сложности в выявлении этиологии низкорослости и назначении соответствующей терапии. Наиболее часто отставание в росте происходит из-за конституциональных особенностей роста и развития данного ребенка. Важно понимать, что факторы задержки могут действовать на организм с момента зачатия до прекращения физиологического процесса роста (19–21 год). Показатель роста является одним из наиболее значимых признаков, характеризующих здоровье ребенка. Его значение – довольно устойчивый признак, но существует сезонная зависимость, связанная с течением заболеваний.
Список литературы
1. Kaganova T. I., Mikhailova E. V., Kuchumova O. V. Growth retardation in children: factors risk and clinical and pathogenetic characteristics of various forms. Pediatrics. Speransky Journal. 2009; 88 (6): 36-9.
2. Dedov I. I., Peterkova V. A., Volevodz N. N. Turner syndrome (pathogenesis, clinical manifestations, diagnosis, treatment). Handbook for doctors. Moscow; 2009.
3. Peterkova V. A., Nagaeva E. V. Experience in the use of growth hormone in various variants of stunting in children. Vopr.Sovrem.pediatrics. 2009; 8 (2): 86-93.
4. Kaganova T. I., Kuchumova O. V. Risk factors for delayed physical development in children. Vopr. Sovrem. pediatrics. 2008; 7 (2): 128–30.
5. Peterkova V. A., Taranushenko T. E., Kiseleva N. G. et al. Evaluation of indicators of physical development in childhood. Honey.advice. 2016; 7: 28-35.
6. Guide to pediatric endocrinology. Edited by C. G. D. Brooke, R. S. Brown.Translated from English.edited by V. A. Peterkova, Moscow: GEOTAR-Media, 2009.
7. Atanesyan R. A., Klimov L.Ya., Uglova T. A., et al. Clinical and laboratory-instrumental diagnostics of growth retardation in children and adolescents. Doctor. 2015; 9: 34-6.
8. Nikitina I. L. Growth hormone in the treatment of stunting in children: results and problems. Polyclinic.2015; 3: 15-2.
9. Bang P., Ahmed S. F., Argente J. et al. Identification and treatment of poor response to growth-promoting therapy in children with low growth. Clindacin (Oxf.) 2012; 77 (2): 169-8.
10. Volevodz N. N. Systemic and metabolic eff ects of growth hormone on children with different variants of stunting [Dissertation]. Moscow; 2005.
Valeology: Health - Illnes - recovery. 2021; : 102-106
CAUSES OF STUNTING IN CHILDREN AND ADOLESCENTS
Abstract
Growth retardation in children is a heterogeneous condition. Its understanding requires a multi-pronged approach and knowledge of the processes that cause the course of this group of diseases. Dwarf growth is considered to be lower than 135 cm in men and less than 125 cm in women. Many endocrine, somatic, genetic and chromosomal diseases are accompanied by growth retardation, as a result of which it is difficult to identify the etiology of stunting and prescribe adequate therapy. Most often, the lag in growth is due to the constitutional features of the child's growth and development. It is important to understand that growth retardation factors can affect the body from the moment of conception to the termination of the physiological growth process (19-21years). Growth is one of the most sensitive indicators that characterize a child's health. Growth is a fairly stable indicator, but there is its seasonal dependence, conjugation with the course of diseases.
References
1. Kaganova T. I., Mikhailova E. V., Kuchumova O. V. Growth retardation in children: factors risk and clinical and pathogenetic characteristics of various forms. Pediatrics. Speransky Journal. 2009; 88 (6): 36-9.
2. Dedov I. I., Peterkova V. A., Volevodz N. N. Turner syndrome (pathogenesis, clinical manifestations, diagnosis, treatment). Handbook for doctors. Moscow; 2009.
3. Peterkova V. A., Nagaeva E. V. Experience in the use of growth hormone in various variants of stunting in children. Vopr.Sovrem.pediatrics. 2009; 8 (2): 86-93.
4. Kaganova T. I., Kuchumova O. V. Risk factors for delayed physical development in children. Vopr. Sovrem. pediatrics. 2008; 7 (2): 128–30.
5. Peterkova V. A., Taranushenko T. E., Kiseleva N. G. et al. Evaluation of indicators of physical development in childhood. Honey.advice. 2016; 7: 28-35.
6. Guide to pediatric endocrinology. Edited by C. G. D. Brooke, R. S. Brown.Translated from English.edited by V. A. Peterkova, Moscow: GEOTAR-Media, 2009.
7. Atanesyan R. A., Klimov L.Ya., Uglova T. A., et al. Clinical and laboratory-instrumental diagnostics of growth retardation in children and adolescents. Doctor. 2015; 9: 34-6.
8. Nikitina I. L. Growth hormone in the treatment of stunting in children: results and problems. Polyclinic.2015; 3: 15-2.
9. Bang P., Ahmed S. F., Argente J. et al. Identification and treatment of poor response to growth-promoting therapy in children with low growth. Clindacin (Oxf.) 2012; 77 (2): 169-8.
10. Volevodz N. N. Systemic and metabolic eff ects of growth hormone on children with different variants of stunting [Dissertation]. Moscow; 2005.
